Loading insider details...
Beta
Latest Form 4 (Oct 2, 2026): Exercise/Conversion of 50,246 NAMS shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 50,246 | n/a |
| Aug 25, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 125,000 | n/a |
| Mar 10, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 104,467 | n/a |
| Feb 24, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale | 14,692 | $514.2K |
| Jan 7, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale | 6,000 | $199.5K |
| Aug 25, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale | 50,000 | $1.21M |
| Mar 28, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/Award | 19,302 | n/a |
| Mar 26, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 150,000 | n/a |
| Jan 7, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/Award | 34,000 | n/a |
| Jan 6, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/Award | 200,000 | n/a |